CAR-T cell capable of secreting PD-1 single-domain antibody to target CD105 as well as preparation method and application of CAR-T cell

By constructing CAR-T cells that secrete PD-1 single-domain antibodies targeting CD105, the problem of poor efficacy of CAR-T cells in the treatment of solid tumors has been solved, achieving highly efficient killing of CD105-positive tumors and enhanced immune response.

CN118909948APending Publication Date: 2024-11-08GUANGXI MEDICAL UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310503188.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current CAR-T cell therapy has not been effective in treating solid tumors, mainly due to the immunosuppressive effect of the tumor microenvironment and the reduced affinity caused by mismatch of single-chain antibodies, making it difficult to effectively target and kill solid tumors.

Method used

CAR-T cells that secrete a PD-1 single-domain antibody targeting CD105 were constructed. The chimeric antigen receptor CD105 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb was expressed in T cells using lentiviral infection technology to enhance their ability to recognize and kill tumor antigens.

Benefits of technology

It improved the killing activity and infiltration capacity of CAR-T cells against solid tumors, reduced T cell depletion, enhanced the immune response at the tumor site, and achieved specific targeting and efficient killing of CD105-positive tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909948A_ABST
    Figure CN118909948A_ABST
Patent Text Reader

Abstract

The invention relates to a CAR-T cell capable of secreting a PD-1 single domain antibody targeting CD105 as well as a preparation method and application of the CAR-T cell, the CAR-T cell is a T cell modified by a chimeric antigen receptor CD105Nb-HIStag-CD8-CD137-CD3zeta-PD-1Nb, and the nucleotide sequence of the chimeric antigen receptor is shown as SEQ ID NO.1. The preparation method of the CAR-T cell comprises the following steps: constructing a recombinant lentiviral vector; according to the CAR-T cell and the preparation method thereof, lentivirus is packaged, lentivirus infected T cells are subjected to in-vitro induction and multiplication culture, engineered CAR-T cells capable of secreting a PD-1 single-domain antibody to target CD105 are obtained, the CD105-PD-1 / Nb CAR-T cell has a good killing effect on CD105 positive tumor cells, the killing effect of the CD105-PD-1 / Nb CAR-T cell on the tumor cells is related to the expression quantity of tumor-related cells CD105, and the CAR-T cell has a good application prospect. And a new strategy is provided for adoptive treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of tumor biological products, and relates to a CAR-T cell (CD105-PD-1 / Nb CAR-T) that secretes a PD-1 single domain antibody targeting CD105 in adoptive immunotherapy, and a preparation method and application thereof. Background Art

[0002] T cells can target tumor cells by expressing chimeric antigen receptors (CAR). By artificially fusing a single-chain antibody that specifically recognizes tumor antigens with the intracellular domain of the receptor that can activate T cells, the "immunoreceptor tyrosine activation motif", into a recombinant gene, a recombinant plasmid is generated, and then transfected into the patient's T cells in vitro through transfection technology, so that the patient's T cells express tumor antigen receptors. This therapy is called CAR-T cell therapy. CAR-T cell therapy is currently the most popular and most valuable treatment for tumor immunotherapy. At present, CAR-T therapy has made great progress in hematological tumors, but due to the complex microenvironment of solid tumors, CAR-T has limited killing effect on solid tumors, so it is necessary to explore new methods to improve the activity of CAR-T in treating solid tumors.

[0003] The basic design of CAR includes tumor-associated antigen binding region, intracellular signaling region, transmembrane region, extracellular hinge region, etc. CAR-T has now developed to the fourth generation and has made good progress in blood tumors. However, for the treatment of solid tumors, the efficacy of CAR-T cells has been poor. One of the important reasons is that tumor-specific T cells find it difficult to break through the immunosuppressive effect of the tumor microenvironment. In addition, most of the CAR antigen recognition parts are composed of single-chain antibodies. Due to the mismatch between the VL and VH of different single-chain antibodies, the affinity of the expressed single-chain antibodies decreases, which is also the reason for the poor effect of CAR-T treatment. Therefore, it is necessary to explore new methods to improve the activity of CAR-T in treating solid tumors, and further study the construction of CD105-PD-1 / Nb CAR-T cells that can specifically recognize tumor antigens and produce efficient anti-cancer effects.

[0004] Nanobodies (single domain antibodies, Nb or VHH) are the smallest functional antigen-specific natural fragments currently available, consisting of approximately 120 amino acids, 4 nm in length and 2.5 nm in diameter. Compared with traditional monoclonal antibodies and Fab fragments (55×10 3 ) or scFv (28×10 3), nano antibodies have a smaller molecular weight, so they have stronger and faster tissue penetration ability, and can reach dense tissues such as solid tumors to play a role. In addition, nano antibodies have the advantages of good stability, high affinity, weak immunogenicity, easy genetic modification, and no problems such as the easy mispairing of traditional antibodies and the need to optimize the heavy chain and light chain connection sequence. They have shown broad application prospects in tumor immunotherapy and other aspects.

[0005] Endothelial cell proliferation-related antigens in the tumor microenvironment have become new targets for immunotherapy of solid tumors. Endoglin (CD105) is strongly expressed on endothelial cells in tumor vascular tissue in a proliferative state, but not expressed or weakly expressed on normal vascular endothelial cells. It is a sign of neovascularization of malignant tumors. Nanoantibodies can improve the penetration of solid tumors due to their small molecular size and strong permeability, and better invade the interior of solid tumors to exert their effects. Therefore, the construction of CAR-T therapy based on CD105 single-domain antibodies has shown good effects on improving solid tumors.

[0006] Programmed death receptor 1 (PD-1), as the key to immunosuppression, has always been the focus of tumor immune microenvironment research, aiming to eliminate its negative effects on T cells and enhance anti-tumor effects. This study constructed a new type of CAR-T cell (named CD105-PD-1 / Nb CAR-T in this article) that secretes PD-1 single-domain antibody targeting CD105, overcoming the inhibitory effect of PD-1 signal in the CD105 Nb CAR-T immune microenvironment, and demonstrated that CAR-T cells based on single-domain antibodies targeting the tumor microenvironment can improve the killing activity of CAR-T cells against solid tumor cells. Summary of the invention

[0007] The purpose of the present invention is to provide an engineered CAR-T cell that secretes a PD-1 single domain antibody targeting CD105. Another purpose is to provide a method for preparing the CAR-T cell and to provide the use of the CAR-T cell in preparing a preparation for treating a tumor.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] A CAR-T cell engineered to secrete a PD-1 single domain antibody targeting CD105, wherein the CAR-T cell is a T cell modified with a chimeric antigen receptor CD105 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb.

[0010] The CAR-T cells secreting PD-1 single domain antibody targeting CD105, wherein the nucleotide sequence of the chimeric antigen receptor CD105Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb is shown in SEQ ID NO.1 in the sequence table.

[0011] A method for preparing the CAR-T cell, the method comprising the following steps: designing a CAR target sequence, obtaining a CAR target sequence fragment of CD105 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES by PCR. Recombining the lentiviral vector GV401 after enzyme digestion with the CAR target sequence obtained by PCR. Transforming the recombinant lentiviral vector into DH5α Escherichia coli, and screening positive clones. Sequencing the positive clones to verify whether the lentiviral vector containing the CD105-PD-1 / Nb CAR-T sequence is successfully constructed. Plasmids are extracted from the recombinant positive clone strains that have been successfully sequenced, and the expression of the CD105-PD-1 / Nb CAR-T sequence in cells is identified by RT-PCR after transfection of 293T cells. After verifying that the recombinant lentiviral vector can be expressed normally, the lentivirus is packaged using a three-plasmid system, the titer is detected, and CAR-T cells are constructed using lentiviral infection technology to allow T cells to express the chimeric antigen receptor.

[0012] A method for preparing CAR-T cells as described above, the method comprising the following steps:

[0013] (1) Construction of recombinant lentiviral vector containing CAR target sequence: The CAR target sequence fragment of CD105 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES was obtained by PCR, and the synthesized fragment was subcloned into the lentiviral vector GV401 after BamHI / EcoRI double digestion. The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the primers on the target gene were used to perform PCR identification on the colonies screened by ampicillin antibiotics. The successfully identified bacterial solution was taken for sequencing. If sequencing was successful, the plasmid was extracted using the Plasmid Mini Kit.

[0014] (2) Lentivirus packaging: Using a three-plasmid system, the plasmid containing the CAR target sequence was co-transfected into 293T cells through two auxiliary plasmids Helper 1.0 and Helper 2.0. After 48 hours, the expression of enhanced green fluorescent protein (EGFP) in the cells was observed under a fluorescence microscope. If fluorescence was successfully expressed, the 293T cell supernatant was collected, concentrated and purified, and the virus concentration was determined by the fluorescence dilution method. The number of EGFP-positive cells was counted, and the virus titer was calculated according to the formula: virus concentration = number of fluorescent cells / volume of virus stock solution in the well.

[0015] (3) T cell preparation: Mononuclear cells are isolated from peripheral blood and cultured to obtain T cells.

[0016] (4) CD105-PD-1 / Nb CAR-T cells: T cells were cultured in a dedicated T cell culture medium containing human CD3 monoclonal antibody, human CD28 monoclonal antibody and human IL-2 cytokine for 24 hours. The next day, the lentivirus solution was added to the stimulated T cells at an MOI of 20 and incubated at 37°C CO 2 After culturing in the incubator for 48 h, the CAR-T cells were placed under a normal microscope to observe the expression of enhanced green fluorescent protein (EGFP) of the CAR-T cells.

[0017] As in the preparation method described above, in step (4), when the amount of T cells infected by the lentivirus accounts for 80-90% of the culture flask, the cells are collected and the medium is replaced, and a complete culture medium with a final concentration of 100 U / mL of IL-2 is added for amplification culture, and the infected cells are identified by flow cytometry.

[0018] As in the preparation method described above, the CAR-T cells are prepared using lentiviral infection technology.

[0019] A use of the CAR-T cells that secrete PD-1 single domain antibodies targeting CD105 in the preparation of preparations for treating tumors.

[0020] As in the above application, preferably, the tumor is a CD105 positive tumor.

[0021] A pharmaceutical composition comprising the CAR-T cells that secrete PD-1 single domain antibody targeting CD105 and a pharmaceutically acceptable carrier.

[0022] A nucleotide sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is CD105 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES.

[0023] A chimeric antigen receptor, wherein the chimeric antigen receptor is CD105 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES.

[0024] The researchers of the present invention found that in the immunotherapy of CD105-positive tumors, the advantage of CAR-T cells that secrete PD-1 single-domain antibodies targeting CD105 is specific targeting, that is, enhancing the targeted recognition of tumor antigens by immune cells. In addition, it also enhances the tumor killing activity dependent on chimeric antigen receptors and the infiltration at the tumor site after infusion, reducing T cell exhaustion. These characteristics possessed by CD105-PD-1 / Nb CAR-T cells originate from the functional structure of chimeric antigen receptors, which mainly include antigen recognition regions and cell activation regions. The intracellular activation region can prolong the survival time of cells in vivo. In addition, the present invention uses lentiviral infection to prepare CAR-T cells, and provides a method for efficiently preparing CD105-PD-1 / Nb CAR-T cells. The CAR-T prepared by this method can stably express chimeric antigen receptors and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the gel electrophoresis diagram of the CD105-PD-1 / Nb CAR gene sequence synthesized by PCR in Example 2 of the present invention, M: Marker; 1: PCR product of the target gene.

[0026] Figure 2 Schematic diagram of the recombinant lentiviral vector in Example 3 of the present invention.

[0027] Figure 3 This is a PCR identification diagram of the DH5α positive clone colony in Example 3 of the present invention, wherein the markers from top to bottom are 5kb, 3kb, 2kb, 1.5kb, 1Kb, 750bp, 500bp, 250bp, and 100bp; P1-P2: positive clone bacteria.

[0028] Figure 4 The expression of CD105-PD-1 / Nb CAR in cells was observed under a fluorescence microscope in Example 4 of the present invention.

[0029] Figure 5 It shows that the T cells in Example 5 of the present invention express EGFP fluorescence after lentiviral transfection.

[0030] Figure 6 The expression of CAR after lentiviral transfection of T cells in Example 5 of the present invention is shown.

[0031] Figure 7 The results show that the T cells in Example 5 of the present invention secrete PD-1 single domain antibodies after lentiviral transfection.

[0032] Figure 8 It shows that the CD105-PD-1 / Nb CAR-T cells in Example 6 of the present invention specifically kill CD105 positive tumor cells. DETAILED DESCRIPTION

[0033] The present invention is further described in detail below in conjunction with specific embodiments. The examples given are only for illustrating the present invention, but not for limiting the scope of the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0034] Example 1 Preparation and activation of T cells

[0035] (1) Density gradient centrifugation to separate peripheral blood T lymphocytes

[0036] Fresh peripheral blood was collected from healthy volunteers using a blood collection tube with anticoagulant, and an equal volume of peripheral blood was mixed with PBS at 37°C. Peripheral blood T lymphocytes were separated by density gradient centrifugation. 4 ml of 37°C sterile lymphocyte separation solution was drawn into a 15 ml centrifuge tube, and 8 ml of diluted peripheral blood was slowly added to the separation liquid surface along the wall of the centrifuge tube. Centrifuge at 2000 rpm for 20 minutes. After the centrifugation, the tube was divided into four layers. The cloudy white film layer cells (PBMC) were carefully drawn along the edge of the centrifuge tube with a Pasteur tube, and the cell suspension was collected into a sterile 50 ml centrifuge tube. Four times the volume of PBS was added and the cells were washed twice. The collected PBMC cells were resuspended with complete cell culture medium RIPM 1640, transferred to a cell culture dish, and cultured in a 37°C cell culture incubator for 2 hours. The suspended cells in the cell culture dish were drawn into another culture dish for culture. The suspended cells were T lymphocytes. T lymphocytes were cultured with complete RIPM 1640 medium containing 100 U / ml rhIL-2.

[0037] (2) T cell culture

[0038] T cells were cultured for 24 hours using a dedicated T cell culture medium containing human CD3, human CD28 monoclonal antibodies, and human IL-2 cytokine.

[0039] Example 2 PCR synthesis of CAR target gene sequence

[0040] The target gene sequence was synthesized and amplified by PCR to obtain the CAR fragment of CD105 / Nb-HIStag-CD8-CD137(4-1BB)-CD3ζ-2A-PD-1Nb-IRES-EGFP, and finally the band of the target fragment was obtained, such as Figure 1 shown.

[0041] Example 3 Construction of recombinant lentiviral vector

[0042] The GV401 vector was digested by double enzyme digestion. After digestion, agarose gel electrophoresis showed that the molecular weight of the lentiviral vector plasmid after digestion was about 8Kd, and the band was clear. The lentiviral vector after digestion was recombined with the CAR target sequence obtained by PCR in Example 2 to obtain a recombinant lentiviral vector, such as Figure 2 The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the target gene were used to perform PCR identification on the colonies screened with ampicillin antibiotics. The PCR product electrophoresis was as shown in Figure 3 As shown, it indicates that the lentiviral recombinant vector plasmid containing the target CAR sequence was successfully constructed. The positive clone bacteria were sequenced and compared to be completely consistent with the target sequence.

[0043] Example 4 Lentivirus packaging

[0044] The recombinant positive clones that were successfully sequenced were extracted with Plasmid Mini Kit and transfected into 293T cells. The expression of CD105-PD-1 / Nb CAR gene sequence in 293T cells was quantitatively examined and analyzed using Real-time Quantitative PCR Detecting System. Figure 4 As shown, obvious enhanced green fluorescence EGFP (200×) can be observed in the transfected 293T cells under a fluorescence microscope, indicating that the CD105-PD-1 / Nb CAR gene sequence is normally expressed in the cells.

[0045] Example 5 Construction of CAR-T cells that secrete PD-1 single domain antibody targeting CD105 (CD105-PD-1 / Nb CAR-T cells)

[0046] (1) Infect T lymphocytes with lentiviral method: T cells were plated into 24-well plates and the cell density in each well was adjusted to 1×10 7 The cells were cultured in a special medium containing 10% FBS, human CD3 monoclonal antibody, human CD28 monoclonal antibody and human IL-2 cytokine for 24 hours, and the lentivirus was added to the stimulated T cells at an MOI of 20. After 48 hours, the expression of EGFP was observed under a fluorescence microscope. Figure 5 As shown, these included CD105-PD-1 / Nb CAR-T cells transfected with lentivirus, CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells (Utd as a negative control).

[0047] (2) Flow cytometry was used to detect the expression of CAR targeting CD105 in T cells secreting PD-1 single domain antibody: 1×10 6After lentiviral transfection, CD105-PD-1 / Nb CAR-T cells, CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells (Utd as negative control) were incubated with PE-anti His tag antibody in the dark, washed three times with PBS, and the expression of HIS-TAG and EGFP fluorescent protein on the surface of CAR-T in each group was detected simultaneously by flow cytometry. The results showed that chimeric antigen receptors were expressed in T cells, such as Figure 6 shown.

[0048] (3) ELISA detection of PD-1 single domain antibody secretion by CAR targeting CD105: The PD-1 single domain antibody secreted by CD105-PD-1 / Nb CAR-T cells is labeled with HIS-TAG. The ELISA method was used to detect the content of HIS-TAG in the culture supernatant of each group of CAR-T cells to determine the secretion of PD-1 single domain antibody. 1×10 6 CD105-PD-1 / Nb CAR-T cells after lentiviral transfection and CAR-T cells without extracellular recognition receptors (Mock), and untransfected T cells Utd as negative control. The specific operation steps are as follows:

[0049] a) Prepare the standard sample as required, with the highest concentration of 200 pg / mL.

[0050] b) Soaking the ELISA plate: Take out the strips to be used, add 300 μL of washing solution to each well and let it soak for 30 seconds, then pat dry on absorbent paper.

[0051] c) Sample addition: Add 200 μL of standard to the standard wells, add 100 μL of cell culture medium to the blank wells, and add 100 μL of the supernatant of the cells to be tested to each sample well.

[0052] d) Add detection antibody: Add 50 μL of diluted antibody to each well, and try to ensure that the sample and detection antibody are added within 15 minutes.

[0053] e) Incubation: After sealing the plate with a sealing film, incubate at room temperature with shaking at 300 rpm for 2 h.

[0054] f) Washing: discard the liquid in the wells, add 300 μL 1× washing solution, let stand for 1 min, discard the liquid in the wells, and then pat dry thoroughly on absorbent paper. Wash 6 times.

[0055] g) Add horseradish peroxidase: Add 100 μL of horseradish peroxidase-labeled streptavidin working solution to each well.

[0056] h) Incubation: Seal the plate with a new sealing film and incubate at room temperature with shaking at 300 rpm for 45 min.

[0057] i) Add substrate for color development: Add 100 μL of color development substrate TMB working solution to each well and incubate for 30 minutes in the dark. j) Add stop solution: Add 100 μL of stop solution to each well. At this time, the liquid in the well changes from blue to yellow, and mix thoroughly.

[0058] k) Result detection: Within 30 minutes, use an ELISA reader to perform dual wavelength detection, measure the maximum absorption wavelength of 450nm and analyze the data. The results are as follows: Figure 7 shown.

[0059] Example 6 Cytotoxicity Analysis of CD105-PD-1 / Nb CAR-T Cells on Human Tumor Cells

[0060] Use PKH26 to stain liver cancer cells Bel7404 and HLCMVEC. Take the CD105-PD-1 / NbCAR-T cells prepared in Example 5 and the T cells cultured in Example 1, respectively. Add the corresponding number of effector T lymphocytes and target cells to a 24-well plate at an effector-target ratio (E:T) of 1:1, 5:1, and 10:1, respectively. After culturing for 16 hours, collect the above cells, add PI dye solution, and incubate at 4°C in the dark for 30 minutes. Centrifuge at 1200rpm for 6 minutes in a high-speed centrifuge, remove the supernatant, add 500μl of PBS to resuspend the cells, PKH26+PI+ means dead cells, and detect the proportion of PKH26+PI+ cells by flow cytometry. Calculate the killing efficiency of CAR-T cells on different cells according to the formula. Among them, the killing rate = 100% × (apoptosis rate of experimental wells - apoptosis rate of natural release wells) / (100 - apoptosis rate of natural release wells), and the natural release wells are target cells without effector cells. As Figure 8 As shown, CD105-PD-1 / Nb CAR-T cells have specific killing activity against tumor cells with high expression of CD105.

[0061] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A CAR-T cell that secretes a PD-1 single domain antibody targeting CD105, It is characterized in that The CAR-T cell is a T cell modified by the chimeric antigen receptor CD105 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb, and the nucleotide sequence of the chimeric antigen receptor CD105 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb comprises the nucleotide sequence shown in SEQ ID NO.

1.

2. The CAR-T cell according to claim 1, wherein the nucleotide sequence of the chimeric antigen receptor CD105Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb is the nucleotide sequence shown in SEQ ID NO.

1.

3. A method for preparing CAR-T cells according to claim 1, It is characterized in that The method comprises the following steps: designing a CAR target sequence, obtaining a CAR target sequence fragment of CD105Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb by PCR, recombining a lentiviral vector after enzyme digestion with the CAR target sequence obtained by PCR, transforming the recombinant lentiviral vector into Escherichia coli, screening positive clones, sequencing the positive clones to verify whether a lentiviral vector containing a CD105 / PD-1Nb CAR sequence is successfully constructed, extracting plasmids from recombinant positive clone strains that have been successfully sequenced, transfecting cells to be transfected, and identifying the expression of the CD105 / PD-1Nb CAR sequence in cells by RT-PCR, verifying that the recombinant lentiviral vector can be expressed normally and then packaging the lentivirus, preparing T cells, and constructing the CAR-T cells by using lentiviral infection technology.

4. A method for preparing CAR-T cells according to claim 3, It is characterized in that The method comprises the following steps: (1) Construction of a recombinant lentiviral vector containing the CAR target sequence: The CAR target sequence fragment of CD105Nb-HIStag-CD8-CD137-CD3ζ-2A-PD-1Nb was obtained by PCR, and the synthesized fragment was subcloned into the lentiviral vector GV401 after BamHI / EcoRI double digestion. The recombinant lentiviral vector was transformed into DH5α Escherichia coli, and the primers on the lentiviral vector and the primers on the target gene were used to perform PCR identification on the colonies screened with ampicillin antibiotics. The successfully identified bacterial liquid was sequenced, and the plasmid was extracted using the Plasmid Mini Kit after sequencing to obtain the plasmid containing the CAR target sequence; (2) Lentivirus packaging: Using a three-plasmid system, the plasmid containing the CAR target sequence was co-transfected into 293T cells through two helper plasmids Helper 1.0 and Helper 2.

0. After 48 hours, the expression of enhanced green fluorescent protein in the cells was observed under a fluorescence microscope. If fluorescence was successfully expressed, the 293T cell supernatant was collected and concentrated and purified. The virus concentration was determined by the fluorescence dilution method, and the number of enhanced green fluorescent protein-positive cells was counted. The virus titer was calculated according to the following formula: virus concentration = number of fluorescent cells / volume of virus stock solution; (3) T cell preparation: Isolate mononuclear cells from peripheral blood and culture them to obtain T cells; (4) CD105-PD-1 / Nb CAR-T cells: T cells were cultured in a dedicated T cell culture medium containing human CD3 monoclonal antibody, human CD28 monoclonal antibody, and human IL-2 cytokine for 24 hours. The next day, the lentiviral solution was added to the T cells at an MOI of 20 and incubated at 37°C CO 2 After culturing in the incubator for 48 h, the CAR-T cells were placed under a normal microscope to observe the expression of enhanced green fluorescent protein in the CAR-T cells.

5. The preparation method according to claim 4, wherein in step (4), when the amount of T cells infected by the lentivirus accounts for 80-90% of the culture flask, the cells are collected and the medium is replaced, and a complete culture medium with a final concentration of 100 U / mL of IL-2 is added for amplification culture, and the infected cells are identified by flow cytometry.

6. Use of the CAR-T cells secreting the PD-1 single domain antibody targeting CD105 as described in claim 1 or 2 in the preparation of a preparation for treating tumors.

7. The use as claimed in claim 6, wherein the tumor is a CD105 positive tumor.

8. A pharmaceutical composition comprising the CAR-T cell according to claim 1 or 2 and a pharmaceutically acceptable carrier.

9. A nucleotide sequence encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is CD105Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb, and the nucleotide sequence is SEQ ID NO.

1.

10. A chimeric antigen receptor, wherein the chimeric antigen receptor is CD105 Nb-HIStag-CD8-CD137-CD3ζ-PD-1Nb, and the chimeric antigen receptor is encoded by the nucleotide sequence shown in SEQ ID NO.1.

Citation Information

Cited By

  • Chimeric antigen receptors targeted to endoglin

    WO2026174137A1